# Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes

> **NCT06889909** · NA · ACTIVE_NOT_RECRUITING · sponsor: **Lahore General Hospital** · enrollment: 102 (actual)

## Conditions studied

- Type 2 Diabetes Mellitus (T2DM)

## Interventions

- **DRUG:** Trelagliptin 100 mg
- **DRUG:** Vildagliptin 50 mg

## Key facts

- **NCT ID:** NCT06889909
- **Lead sponsor:** Lahore General Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-15
- **Primary completion:** 2025-06-15
- **Final completion:** 2025-06-15
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-03-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06889909

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06889909, "Comparison of Once-Weekly Trelagliptin Vs. Once-Daily Vildagliptin for HbA1c Reduction in Type 2 Diabetes". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06889909. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*